Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glecaprevir/pibrentasvir for the treatment of hepatitis C virus infection

Next Previous
X
Search
Trial Profile

Glecaprevir/pibrentasvir for the treatment of hepatitis C virus infection

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glecaprevir/pibrentasvir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms Grand plan study

    • Most Recent Events

    • 08 Nov 2022 Results (n=116) assessing the safety and efficacy and any effect of HCV treatment on adverse events resulting from ongoing street opioid use, presented at The Liver Meeting 2022: 73rd Annual Meeting of the American Association for the Study of Liver Diseases.
    • 26 Jun 2022 Results assessing a community-based program targeting HCV-infected innercity residents with active fentanyl use, presented at The International Liver Congress 2022.
    • 15 Nov 2021 Status changed from active, no longer recruiting to completed, according to results presented at The Liver Meeting 2021: 72nd Annual Meeting of the American Association for the Study of Liver Diseases.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top